Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Pfizer ( (PFE) ) is now available.
On November 13, 2025, Pfizer completed its acquisition of Metsera, Inc., a Delaware-based company, for approximately $7.0 billion. The acquisition includes contingent value rights for additional payments tied to the achievement of specific milestones related to Metsera’s GLP-1 receptor antagonist and amylin analog therapies, potentially impacting Pfizer’s strategic positioning in the pharmaceutical industry.
The most recent analyst rating on (PFE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pfizer stock, see the PFE Stock Forecast page.
Spark’s Take on PFE Stock
According to Spark, TipRanks’ AI Analyst, PFE is a Neutral.
Pfizer’s overall stock score reflects strong valuation and income potential, supported by a high dividend yield and attractive P/E ratio. However, financial performance is challenged by declining revenue and cash flow, and technical indicators suggest weak momentum. The earnings call highlighted strategic initiatives but also underscored ongoing challenges, particularly in COVID-19 product revenues and legal issues.
To see Spark’s full report on PFE stock, click here.
More about Pfizer
Pfizer Inc. is a leading pharmaceutical company known for developing and manufacturing a wide range of healthcare products, including vaccines, medicines, and consumer health products, with a strong focus on innovation and global health solutions.
Average Trading Volume: 62,197,497
Technical Sentiment Signal: Hold
Current Market Cap: $147.1B
Find detailed analytics on PFE stock on TipRanks’ Stock Analysis page.